Robotic and computer-assisted surgical solutions continued to thrive. Thanks to Mazor, Medtronic can attempt to build a fully-integrated procedural solution for spine surgery planning, execution, and confirmation. DePuy Synthes underscored its commitment to robotics by acquiring Orthotaxy, whose small, portable robotic system notably doesn’t require CT scans or special technicians. Globus fortified its ExcelsiusGPS computer-assisted surgery system by purchasing the Surgimap software platform, which helps plan and simulate outcomes while treating complex spinal deformities through a cloud-based infrastructure with predictive algorithms and visual guides. In a similar vein, NuVasive gained an FDA nod for its Pulse automation platform for spine surgery, which combines 2D and 3D navigation and smart imaging, neuromonitoring, surgical planning, radiation reduction, and patient-specific rod bending technologies.
Some of the Top 10 experienced the FDA’s wrath last year. The agency slapped Zimmer Biomet with a warning letter last August over quality control issues in the company’s Warsaw facility. Globus subsidiary Human Biologics of Texas, which makes the firm’s ViaCell allograft, also came under fire last Halloween for failures to document and investigate production deviations.
We hope you enjoy reading this year’s Top 10 report.
Editors’ note: As you read our report, please take note that while the companies are ranked according to sales reported for their most recent fiscal year, some may include non-device sales within a division, such as combination products, drug delivery, software, or device-related services. Not all companies explicitly break out the device portion of total revenues. We consulted numerous public documents and contacted company officials as needed to arrive at the best estimates.
TOP ORTHOPEDIC DEVICE FIRMS
|2. DePuy Synthes||$8.88B|
|3. Zimmer Biomet||$7.93B|
|4. Smith & Nephew||$4.90B|
|5. Medtronic Spine||$2.65B|
|7. Wright Medical||$836M|
|8. Globus Medical||$713M|
|10. Integra LifeSciences||$509M|